Kingsview Wealth Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Kingsview Wealth Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,806	Closed	-$457K	–	1166
2024 Q3	$457K	Sell	4,806 -60	-1%	-$5.7K	0.01%	753
2024 Q2	$445K	Sell	4,866 -25,328	-84%	-$2.26M	0.01%	721
2024 Q1	$2.74M	Buy	30,194 +27,687	+1,104%	+$2.42M	0.07%	261
2023 Q4	$204K	Sell	2,507 -530	-17%	-$41.6K	0.01%	902
2023 Q3	$243K	Hold	3,037	–	–	0.01%	826
2023 Q2	$239K	Hold	3,037	–	–	0.01%	812
2023 Q1	$236K	Hold	3,037	–	–	0.01%	787
2022 Q4	$236K	Hold	3,037	–	–	0.01%	743
2022 Q3	$204K	Hold	3,037	–	–	0.01%	757
2022 Q2	$233K	Buy	+3,037	New	+$237K	0.01%	729

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Kingsview Wealth Management's PPH Position: Q4 2024 in Review

Kingsview Wealth Management sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2024, closing a stake of 4,806 shares — an estimated $457K sold.

Kingsview Wealth Management first reported a position in PPH in Q2 2022 and held it in 10 quarters. The position peaked at $2.74M in Q1 2024. 142 funds tracked by Wall St. Rank hold PPH as of Q4 2024.

Kingsview Wealth Management reported no remaining VanEck Pharmaceutical ETF position as of Q4 2024 after selling out during the quarter.
Kingsview Wealth Management sold 4,806 VanEck Pharmaceutical ETF shares in Q4 2024, an estimated $457K.
Kingsview Wealth Management first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and held it in 10 quarters.
Kingsview Wealth Management's VanEck Pharmaceutical ETF position peaked at $2.74M in Q1 2024.
142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2024.

Based on Kingsview Wealth Management's 13F filing for Q4 2024, filed 28 Jan 2025.